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In this issue of Immunity, Haniffa et al. (2012) identify the presence of professional cross-presenting human
dendritic cells in the skin, the liver, and the lung and also presented comparative genomics to align human
and mouse dendritic cell types across tissues.Mouse dendritic cell (DC) subsets have
been very well characterized in the last
10 years and can be classified in five
major subsets that exist both in lymphoid
and nonlymphoid tissues (Guilliams et al.,
2010). The CD8a-type DC is particularly
efficient at cross-presenting exogenous
antigens for the activation of CD8+
T lymphocytes. Until recently (Segura
et al., 2012), the DCs migrating from
human nonlymphoid tissues into their
draining lymph nodes had not been well
characterized, except for Langerhans
cells (LCs). The delineation of homologies
between human and mouse DC subsets
had been hampered by differences in
surface marker expression and in acces-
sibility of equivalent tissues as a source
for these cells. However, by using an
approach as broad and unbiased as
possible for comparing immune cell types
across species, namely functional geno-
mics, we succeeded in aligning human
blood and mouse spleen DC subsets
(Robbins et al., 2008), thereby revealing
that the human DC subset expressing
high CD141 (BDCA3) is the equivalent to
mouse CD8a-type DCs. This discovery
was confirmed at the functional level as
well as by identifying markers specific
for these cell types and conserved across
species, in particular the endocytic C-
type lectin receptor CLEC9A (Caminschi
et al., 2008; Sancho et al., 2008) and the
chemokine receptor XCR1 (Bachem
et al., 2010; Crozat et al., 2010). A similar
conservation of DC subsets was reported
for sheep skin-draining lymph and skin
(Contreras et al., 2010). Hence, a universal
and simplified classification of DC sub-
sets in fivemajor populations, irrespective
of the tissues and species of origin, wasproposed (Guilliams et al., 2010). It
predicted that CD11chiCD1a+CD141hi
CLEC9A+TLR3hi DCs exist in the tissue
parenchyma of human nonlymphoid
organs, which would be the professional
cross-presenting human DCs, more
generally specialized in the activation of
CD8+ T lymphocytes, and is able to
produce IL-12p70 more efficiently than
the other DC subsets. No experiments
had yet been reported to rigorously test
this hypothesis.
If human professional cross-presenting
DCs exist in epithelia, they would consti-
tute the most functionally and anatomi-
cally relevant population of human DCs
to target clinically to induce efficient
CD8+ T cell responses against intracel-
lular pathogens or tumors. Hence, ad-
dressing this point is of major importance.
However, designing experiments to seek
for human professional cross-presenting
DCs in nonlymphoid tissues is a major
challenge because it requires overcoming
many issues. First, it is difficult to access
human tissues in sufficient quantities
and of high enough quality, knowing that
the frequency of human professional
cross-presenting DCs is expected to be
extremely low in nonlymphoid tissues as
in lymphoid organs. Second, optimized
protocols have to be set up to efficiently
isolate and rigorously phenotype epithe-
lial DCs. Third, appropriate functional
tests must be designed to evaluate the
relative cross-presentation efficiency of
different DC subsets despite their differ-
ence in susceptibility to apoptosis and in
expression of innate immune recognition
receptors.
In this issue of Immunity, Haniffa et al.
(2012) have succeeded in this challenge,Immuperforming a tour-de-force study to seek
for professional cross-presenting DCs in
human skin, skin-draining lymph nodes,
liver, and lung and to characterize in
depth the DC subsets from human skin,
by comparison with human blood. The
authors used (1) CD11c, HLA-DR, CD14,
CD1a, CD1c, CD141, CLEC9A, XCR1,
and other markers for rigorous and
detailed phenotypic identification of DC
subsets in lineage cells from various
human tissues (Figure 1), (2) a functional
assay for evaluating the cross-presenta-
tion capacity of human blood and skin
DC subsets, (3) allogeneic mixed lympho-
cyte reactions to measure skin DC sub-
set ability to activate CD4+ and CD8+
T cells, (4) different stimuli to probe the
pattern of cytokine production by skin
DC subsets, (5) cell cycle analysis, and
phenotypic characterization of blood
DC subsets upon incubation with digest-
ing skin, to investigate the potential
precursor-progeny relationship between
blood and skin CD141hi DCs, and (6)
comparative genomics to explore the
relationships between human and mouse
DC subsets from different tissues.
Haniffa et al. (2012) show that the
CD141hiCLEC9A+XCR1+ DCs are much
more potent for cross-presentation of
soluble hepatitis B surface antigen
than any of the other four subsets of
human skin antigen-presenting cells
(APCs) examined, including LCs. Indeed,
CD141hiCLEC9A+XCR1+ DCs are at least
as potent for cross-presentation as the
DCs derived in vitro from monocytes,
the gold standard to look at cross-
presentation by human APCs. Previously,
LCs had been proposed to be the skin
APC subset that was the most potent fornity 37, July 27, 2012 ª2012 Elsevier Inc. 3
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Figure 1. Accelerating Knowledge Transfer
from Mouse to Human for the Identification
and Study of Professional Cross-Presenting
DCs
Human CD141hi and mouse CD8a-type DCs
express species- and tissue-specific membrane
markers, which were initially used to identify them
but made it more difficult to align populations
across tissues and species. Markers in black are
conserved across tissues within a species.
Markers in green vary even in a given species,
between tissues. Haniffa et al. (2012) now show
that CD8a-type DCs exist in human nonlymphoid
tissues, particularly in the skin, and refine the
previous demonstration that CD8a-type DCs bear
a number of conserved phenotypic markers (red),
particularly the endocytic C-type lectin receptor
CLEC9A, the chemokine receptor XCR1, and the
endosomal Toll-like receptor TLR3. Both human
and mouse XCR1+CLEC9A+ DCs produce IL-28
and CXCL10 upon TLR3 triggering, but only mouse
DCs produce IL-12. Hence, a universal nomencla-
ture could be proposed to identify those cells on
the basis of their XCR1+CLEC9A+ phenotype.
Focusing investigations on the functional study
on molecules harboring a selective conserved
expression in CD8a-type DCs across tissues and
species will help accelerate our understanding of
the biology of cross-presenting DCs.
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of the study of in vitro-derived LCs and
CD1a+CD14+ cells. The study by Haniffa
et al. should now prompt researchers
to target CD141hiCLEC9A+XCR1+ DCs for
skin vaccination and for comparison with
ongoing trials targeting LCs. The observa-
tion that human CD141hiCLEC9A+XCR1+
DCs are much more potent at cross-
presentation than LCs is consistent with
previous observations in mice (Guilliams
et al., 2010). This illustrates how much
human immunology we can learn from4 Immunity 37, July 27, 2012 ª2012 Elsevierthe study of mouse models, provided
that appropriate strategies are used to
help focus on biological processes with
a high probability of cross-species con-
servation (Crozat et al., 2010). The inability
of other human skin APC subsets to
perform cross-presentation as reported
by Haniffa et al. might result in part from
the stimuli and/or from the mode of
antigen delivery used. Further studies
will be required to investigate this, in-
cluding the ability of human skin DC
subsets to present antigens derived
from dead cells upon exposure to
different adjuvants. Regardless, CD141hi
CLEC9A+XCR1+ DCs are more potent at
cross-presentation under different stimu-
lation conditions. Other surprises re-
vealed in the study by Haniffa et al. are
that skin CD141hiCLEC9A+XCR1+ DCs
harbor low expression of CD11c, are
CD1c+, and do not produce IL-12 (Fig-
ure 1), contrary to expectations (Guilliams
et al., 2010). These factors may have
impeded the identification of human skin
CD141hiCLEC9A+XCR1+ DCs by others.
This also raises the question of which
cytokines are the most important as a
third signal for functional polarization of
T cells by CD141hiCLEC9A+XCR1+ DCs.
IL-28 or CXCL10 might be implicated,
given that they are produce by both
human and mouse XCR1+CLEC9A+ DCs
(Figure 1).
By using comparative genomics to
align human and mouse cell types,
Haniffa et al. demonstrated that human
skin and blood CD141hiCLEC9A+XCR1+
DCs are closely related to one another
and to mouse CD8a-type DCs. They
also showed that human skin HLA-
DR+CD14+ cells bear a gene signature
in common with human blood CD14+
monocytes, mouse monocytes, and
mouse lung CD11b+ cells, but not with
mouse spleen CD4+ DCs. This sug-
gests that, like LCs, human skin HLA-
DR+CD14+ cells derive from monocytes
and do not belong to the same lineage
as CD8a- and CD4-type DCs. This may
explain why CD141hiCLEC9A+XCR1+
DCs have not been found in the cultures
used to differentiate LCs and CD1a+
CD14+ cells from human CD34+ progeni-
tors. The growth factor and cytokine com-
bination used in these cultures probably
promotes the differentiation of cells of
the monocyte lineage and prevents that
of other DCs. Hence, under these condi-Inc.tions it is not possible to study the whole
spectrum of human skin APC subsets
and cross-presentation segregated with
LCs because of the absence of the cells
the most potent for these function, the
CD141hiCLEC9A+XCR1+ DCs. For better
dissection of the functions of human skin
APC subsets, it will be critical to develop
protocols to differentiate them all in vitro
in a single culture system.
Other key questions remain open
regarding the biology of XCR1+CLEC9A+
DCs and their targeting for clinical use.
CLEC9A recognizes F-actin exposed on
necrotic cells and contributes to confer
to XCR1+CLEC9A+ DCs their unique
efficacy for cross-presentation to CD8+
T cells of dead cell-derived antigens,
probably through induction of Syk acti-
vation in DCs. However, precisely how
CLEC9A promotes cross-presentation of
engulfed antigens is unknown. CLEC9A
may shuttle antigens into the same endo-
somes where TLR3 is located. Coordina-
tion of antigen delivery into, and TLR3
signaling from, these endosomes might
be required to optimize cross-presenta-
tion efficiency. We ignore whether certain
chemotherapeutic agents used to treat
cancer patients are more potent than
others to promote cross-presentation
of dying tumor cells specifically by
XCR1+CLEC9A+ DCs. How the inter-
action between XCR1 and XCL1 pro-
motes the activation of CD8+ T cell
responses by DCs is not known. These
questions are not only important for the
basic understanding of the biology of
XCR1+CLEC9A+ DCs but also to design
appropriate strategies to harness them
in the clinic for vaccination or immuno-
therapy. Importantly, the mouse should
be a good preclinical model to design
such strategies, given that it will be
possible to target the same conserved
membrane receptors, i.e., CLEC9A and
XCR1, to specifically deliver antigens
through antibodies to mouse and human
professional cross-presenting DCs, and
the same adjuvants to activate them,
e.g., poly(I:C) for TLR3 triggering and
R848 for TLR8 triggering. Both the cellular
and humoral arms of adaptive immunity
are required for efficient control of many
intracellular pathogens. It is very encour-
aging that, in mice, CLEC9A targeting is
very efficient not only for the activation
of CD8+ T cells by cross-presentation to
induce killing of infected or tumor cells
Immunity
Previewsbut also for the induction of strong anti-
body responses.
The study by Haniffa et al. will be
a landmark in the quest for the identifica-
tion and functional characterization of
DC subsets in human nonlymphoid
organs and their draining lymph nodes. It
significantly advanced the model of DC
subset classification across species and
tissues previously proposed (Guilliams
et al., 2010). It will help the effort put
forward by international experts to
define an official nomenclature for these
cell types (Ziegler-Heitbrock et al., 2010;
Figure 1). Last but not least, the dis-
covery of professional cross-presenting
CD141hiCLEC9A+XCR1+ DCs in human
skin has major implications for the clinic,
given that targeting of these cells for
vaccination purposes could be achieved
through intradermal administration as
a convenient and physiological route for
the delivery of antigen and adjuvant. Ascompared to systemic vaccination, this
strategy might allow decreasing of the
doses required to induce immunity,
and hence reduce side effects, while
facilitating the development of mucosal
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The mechanisms linking skin inflammation and observed defects in skin barrier function and integrity need
further elucidation. In this issue of Immunity, Lai et al. (2012) identify REG3A as a downstream mediator of
interleukin 17A that enhances keratinocyte proliferation and downmodulates keratinocyte differentiation.Psoriasis (psoriasis vulgaris) is a chronic
inflammatory disease of the skin charac-
terized by the presence of raised ery-
thematous scaly plaques (see Nestle
et al. [2009] for a review). Histological
examination of the skin of patients with
psoriasis reveals inflammatory cellular
infiltrates in the dermis and a thickened
hyperproliferative epidermis. The kerati-
nocytes in the epidermis exhibit aberrant
maturation, with an increased rate of
mitosis for the basal keratinocytes, and
an incomplete cornification of the kerati-
nocytes that form the uppermost epi-
dermal layer. The inflammatory infiltrateincludes plasmacytoid dendritic cells,
macrophages, neutrophils, and T cells
that express T helper-1 (Th1) and T
helper-17 (Th17) cell-derived cytokines.
Th17 cell responses have been linked
to psoriasis by human genetic and clinical
studies. Th17 cells express the IL-23
receptor, and IL-23 is critical for mainte-
nance of the Th17 cell phenotype and
for expansion of Th17 cell populations
(Miossec et al., 2009), and variations in
the genes encoding the shared p40
subunit of IL-12 and IL-23 and the IL-23
receptor have been associated with
susceptibility to psoriasis (see Nestleet al. [2009]). Blockade of IL-12 and IL-
23 with ustekinumab, which targets the
shared p40 subunit of these cytokines,
in psoriasis patients improves disease
scores, implicating Th1- and/or Th17 cell-
derived cytokines in disease pathology
(Nestle et al., 2009).
Th17 cells express both IL-17A and
IL-17F, which can form either homo-
dimers or heterodimers, and can bind to
the IL-17 receptor complex comprised
of IL-17 receptor A (IL17RA) and IL-17
receptor C (IL17RC) to signal to cells
(Miossec et al., 2009). Recent clinical
studies evaluating the blockade ofnity 37, July 27, 2012 ª2012 Elsevier Inc. 5
